

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
21144-706SERIAL NO.
09/439,293LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT(S)' INFORMATION DISCLOSURE

STATEMENT

(Use several sheets if necessary)

INVENTOR

Cabot, Myles C. et al.

FILING DATE

November 12, 1999

GROUP ART UNIT

1635

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	Subclass	TRANSLATN
							yes no

OTHER ART (Include Author, Title, Date, Pertinent Pages, etc.)

Q3	C1	Lucci et al., "Modification of Ceramide Metabolism Increases Cancer Cell Sensitivity to Cytotoxics," <i>International Journal of Oncology</i> , 15: 541-546 (1999).
Q3	C2	Lucci et al., "Multidrug Resistance Modulators and Doxorubicin Synergize to Elevate Ceramide Levels and Elicit Apoptosis in Drug-Resistant Cancer Cells," <i>Cancer</i> , Volume 86, Number 2 (1999).

EXAMINER Q3 DATE CONSIDERED 1/16/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant(s).

(Information Disclosure Statement — Section 9 PTO-1449 (Modified) [6-1])

PAGE 1 of 1

RECEIVED
JAN 11 1998
TECHNICAL SERVICES

FORM PTO-1449 (Modified)

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT(S)' INFORMATION DISCLOSURE
STATEMENT

(Use several sheets if necessary)

ATTY. DOCKET NO.
21144-706

SERIAL NO.
09 439,293

INVENTOR
Cabot, Myles C. et al.

FILING DATE
November 12, 1999

GROUP ART UNIT
1635

REFERENCE DESIGNATION U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	Subclass	Filing Date If Appropriate
9-3	A1	5,677,337	October 14, 1997	Wei et al.	514	546	
9-3	A2	5,677,341	October 14, 1997	Lyons	514	558	
9-3	A3	5,885,786	March 23, 1999	Cabot	435	7.21	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	Subclass	TRANSLATIN	
							yes	no
9-3	B1	WO 95/21175 A	August 10, 1995	PCT				
9-3	B2	WO 97/10817 A	March 27, 1997	PCT				
9-3	B3	WO 97/40358 A	October 30, 1997	PCT				
9-3	B4	WO 99/28747	June 10, 1999	PCT				
9-3	B5	WO 99/07855 A	February 18, 1999	PCT				

OTHER ART (Include Author, Title, Date, Pertinent Pages, etc.)

9-3	C1	Abe et al., "Metabolic Effects of Short-Chain Ceramide and Glucosylceramide on Sphingolipids and Protein Kinase C," <i>Eur. J. Biochem.</i> , 210:765-773 (1992)
9-3	C2	Abe et al., "Structural and Stereochemical Studies of Potent Inhibitors of Glucosylceramide Synthase and Tumor Cell Growth," <i>Journal of Lipid Research</i> , 36:611-621 (1995)
9-3	C3	Bose, R. et al., "Ceramide Synthase Mediates Daunorubicin-Induced Apoptosis: An Alternative Mechanism for Generating Death Signals" <i>Cell</i> 82:405-414 (1995)
9-3	C4	Breimer et al., "The Specific Glycosphingolipid Composition of Human Ureteral Epithelial Cells", <i>J. Biochem.</i> , 98(5):1169-1180 (1985)
9-3	C5	Cabot et al., "Tamoxifen Retards Glycosphingolipid Metabolism in Human Cancer Cells", <i>FEBS Letters</i> 394:129-131 (October 1, 1996)
9-3	C6	Cabot, M.C. et al., "Apoptosis - A Cell Mechanism Important for Cytotoxic Response to Adriamycin and a Lipid Metabolic Pathway That Facilitates Escape", <i>Breast Cancer Resistance Treatment</i> , Vol 46(1):Abstract 283, pg. 71 (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant(s).

(Information Disclosure Statement — Section 9 PTO-1449 (Modified) [6-1])

PAGE 1 of 4

52037702
Docket No. 21144-706

FORM PTO-1449 (Modified)

ATTY. DOCKET NO.
21144-706SERIAL NO.
09 439.293LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT(S) INFORMATION DISCLOSURE
STATEMENT
(Use several sheets if necessary)INVENTOR
Cabot, Myles C. et alFILING DATE
November 12, 1999GROUP ART UNIT
1635

OTHER ART (Include Author, Title, Date, Pertinent Pages, etc.)

J3	C7	Cai, Z. et al., "Alteration of the Sphingomyelin Ceramide Pathway is Associated with Resistance of Human Breast Carcinoma MCF7 Cells to Tumor Necrosis Factor- β -Mediated Cytotoxicity" <i>The Journal of Biological Chemistry</i> , 272:6918-6926 (1997)
	C8	Callaghan and Higgins, "Interaction of Tamoxifen with the Multidrug Resistance P-Glycoprotein." <i>British Journal of Cancer</i> , 71:294-299 (1995)
	C9	Chatterjee and Harris, "Reversal of Acquired Resistance to Adriamycin in CHO Cells by Tamoxifen and 4-Hydroxy Tamoxifen: Role of Drug Interaction with Alpha 1 Acid Glycoprotein," <i>Br. J. Cancer</i> , 62:712-717 (1990)
	C10	Cheresh et al., "Localization of the Gangliosides GD ₂ , and GD ₃ , in Adhesion Plaques and on the Surface of Human Melanoma Cells," <i>Proc. Nat'l Acad. Sci. USA</i> , 81:5767-5771 (Sep., 1984)
	C11	Chuma, S. J. et al., "Loss of Ceramide Production Confers Resistance to Radiation-induced Apoptosis." <i>Cancer Research</i> 57:1270-1275 (1997)
	C12	de Chaves, et al., "Elevation of Ceramide Within Distal Neurites Inhibits Neurite Growth in Cultured Rat Sympathetic Neurons". <i>Journal of Biological Chemistry</i> , Vol. 272, No. 5, pp. 3028-3035 (1967)
	C13	Dyatlovitskaya et al., "Sphingolipids and Malignant Growth" <i>Biochemistry (Moscow)</i> 60(6): 629-633 (June 1995)
	C14	Escriba et al., "Role of Membrane Lipids on the Interaction of Daunomycin with Plasma Membranes from Tumor Cells: Implications in Drug-Resistance Phenomena." <i>Biochemistry</i> , 29:7275-7282 (1990)
	C15	Ford et al., "Structural Features Determining Activity of Phenothiazines and Related Drugs for Inhibition of Cell Growth and Reversal of Multidrug Resistance," <i>Molecular Pharmacology</i> , 35:105-115 (1988)
	C16	Hannun, Y. et al., "The Sphingomyelin Cycle and the Second Messenger Function of Ceramide". <i>The Journal of Biological Chemistry</i> 269:3125-3128 (1994)
	C17	Hannun and Obeid, "Ceramide: an Intracellular Signal for Apoptosis". <i>Trends Biochemical Science</i> 20:73-77 (1995)
	C18	Holleran et al., "Characterization of Cellular Lipids in Doxorubicin-Sensitive and -Resistant P388 Mouse Leukemia Cells" <i>Cancer Chemotherapy and Pharmacology</i> 17(1):11-15 (May 1986).
	C19	Ikushima et al., "Effects of Polyunsaturated Fatty Acids on Vincristine-Resistance in Human Neuroblastoma Cells." <i>AntiCancer Research</i> , 11:1215-1220 (1991)
	C20	Inokuchi et al., "Effects of D-Threo-PDMP, an Inhibitor of Glucosylceramide Synthetase, on Expression of Cell Surface Glycolipid Antigen and Binding to Adhesive Proteins by B16 Melanoma Cells." <i>Journal of Cellular Physiology</i> , 141:573-583 (1989)
↓	C21	Inokuchi et al., "Antitumor Activity Via Inhibition of Glycosphingolipid Biosynthesis" <i>Cancer Letters</i> 38:23-30 (December 1987)

EXAMINER

DATE CONSIDERED 11/11/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant(s).

FORM PTO-1449 (Modified)

**LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT(S) INFORMATION DISCLOSURE
STATEMENT**
(Use several sheets if necessary)

ATTY. DOCKET NO.
21144-706

SERIAL NO.
09 439.293

INVENTOR
Cabot, Myles C. et al

FILING DATE
November 12, 1999

GROUP ART UNIT
1635

OTHER ART (Include Author, Title, Date, Pertinent Pages, etc.)

✓	C22	Inokuchi and Radin, "Preparation of the Active Isomer of 1-Phenyl-2-Decanoylamino-3-Morpholino-1-Propanol, Inhibitor of Murine Glucocerebroside Synthetase," <i>Journal of Lipid Research</i> , 28:565-571 (1987)
	C23	Jaffrézou et al., "Inhibition of Lysosomal Acid Sphingomyelinase by Agents Which Reverse Multidrug Resistance," <i>Biochimica et Biophysica Acta</i> 1266:1-8 (1995)
	C24	Jarvis, W. D. et al., "Ceramide and the Induction of Apoptosis", <i>Clin. Cancer Research</i> 2:1-6 (1996)
	C25	Kajiji et al., "Structurally Distinct MDR Modulators Show Specific Patterns of Reversal Against P-Glycoproteins Bearing Unique Mutations at Serine," <i>Biochemistry</i> , 33(17):5041-5048 (1994)
	C26	Kirk et al., "Reversal of P—Glycoprotein—Mediated Multidrug Resistance By Pure Anti-Oestrogens and Novel Tamoxifen Derivatives," <i>Biochemical Pharmacology</i> , 48(2):277-285 (1994)
	C27	Kolesnick and Golde., "The Sphingomyelin Pathway in Tumor Necrosis Factor and Interleukin-1 Signaling", <i>Cell</i> 77:325-328 (1994)
	C28	Lavie et al., "Accumulation of Novel Sphingoid Bases in Multidrug-Resistant (MDR) Human Breast Cancer MCF-7 Cells" <i>Proc. Annu. Meet. Am. Assoc. Cancer Inst.</i> 37:A2247:XP-002100453 (1996).
	C29	Lavie et al., "Agents that Reverse Multidrug Resistance, Tamoxifen, Verapamil and Cyclosporin A, Block Glycosphingolipid Metabolism by Inhibiting Ceramide Glycosylation in Human Cancer Cells" <i>The Journal of Biological Chemistry</i> 272(3):1682-1687 (January 17, 1997).
	C30	Lavie et al., "Accumulation of Glucosylceramides in Multidrug-resistant Cancer Cells", <i>The Journal of Biological Chemistry</i> 271:19530-19536 (1997)
	C31	Le Moyec et al., "Proton Nuclear Magnetic Resonance Spectroscopy Reveals Cellular Lipids Involved in Resistance to Adriamycin and Taxol by the K562 Leukemia Cell Line," <i>Cancer Research</i> , 56:3461-3467 (1996)
	C32	Lloyd et al., "Cell Surface Accessibility of Individual Gangliosides in Malignant Melanoma Cells to Antibodies Is Influenced by the Total Ganglioside Composition of the Cells," <i>Cancer Research</i> , 52:4948-4953 (Sep. 1992)
	C33	Lucci, A. et al., "Glucosylceramide: a Marker for Multiple-Drug Resistant Cancers", <i>Anticancer Research</i> Jan-Feb: 18(1B) 475-480 (1998)
	C34	Madhavi and Das, "Effect of n-6 and n-3 Fatty Acids on the Survival of Vincristine Sensitive and Resistant Human Cervical Carcinoma Cells In Vitro," <i>Cancer Letters</i> , 84:31-41 (1994)
✓	C35	McKibbin et al., "Glycosphingolipids of Cultured Human Colon Carcinoma Cells and Their Drug-Resistant Sublines", <i>Biochimica et Biophysica Acta</i> , 958:235-246, 1988.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant(s).

(Information Disclosure Statement — Section 9 PTO-1449 (Modified) [6-1])

PAGE 3 of 4

52037792
Docket No.: 21144-706

FORM PTO-1449 (Modified)

**LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT(S) INFORMATION DISCLOSURE
STATEMENT**
(Use several sheets if necessary)

ATTY. DOCKET NO.
21144-706

SERIAL NO.
09 439,293

INVENTOR
Cabot, Myles C. et al

FILING DATE
November 12, 1999

GROUP ART UNIT
1635

OTHER ART (Include Author, Title, Date, Pertinent Pages, etc.)

97	C36	Michael, J. M. et al., "Resistance to Radiation-Induced Apoptosis in Burkitt's Lymphoma Cells is Associated with Defective Ceramide Signaling", <i>Cancer Research</i> 57:3600-3605 (1997)
	C37	Nakamura, S. et al., "Dual Roles of Sphingolipids in Signaling of the Escape from and Onset of Apoptosis in a Mouse Cytotoxic T-cell Line, CTLL-2", <i>The Journal of Biological Chemistry</i> 271:1255-1257 (1996)
	C38	Santana, P. et al., "Acid Sphingomyelinase-Deficient Human Lymphoblast and Mice are Defective in Radiation-Induced Apoptosis", <i>Cell</i> 86:189-199 (1996)
	C39	Wyllie, A. H. et al., "Apoptosis and Carcinogenesis", <i>Eur. J. Cell. Biol.</i> 73:189-197 (1997)
↓	C40	Zyad, A. et al., "Resistance to TNF- α and Adriamycin in the Human Breast Cancer MCF-7 Cell Line: Relationship to <i>MDR1</i> , MnSOD, and TNF Gene Expression", <i>Cancer Research</i> 54:825-831 (1994)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant(s).

(Information Disclosure Statement — Section 9 PTO-1449 (Modified) [6-1])

PAGE 4 of 4